Pharmaceutical lobby groups may delay codeine ruling

SMH, 3 October 2016
Author: Daniel Burdon
“The Therapeutic Goods Administration’s Advisory Committee on Medicines Scheduling in October last year made an interim decision to remove codeine-containing products from over-the-counter sales from June this year, citing growing evidence of codeine-related harm. Last November the authority quietly bowed to a push from the Pharmacy Guild, the Pharmaceutical Society of Australia and the Australian Self Medication Industry to complete a “regulation impact statement” (RIS) of the interim decision. While patient safety, abuse potential and public health were the committee’s key considerations, the RIS process focuses on the potential financial costs and demands.”
Find article here.